GSK plc Sponsored ADR (GSK)
GSK settles another Illinois Zantac lawsuit
British drugmaker GSK on Monday said it has agreed to confidentially settle a lawsuit in Illinois alleging its discontinued heartburn drug Zantac caused cancer, the latest in a series of settlements to end costly litigation.
Here's Why GSK (GSK) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
EU regulator recommends use of GSK's RSV shot in adults aged 50 to 59
The European Union health regulator on Friday recommended expanded use of GSK's respiratory syncytial virus (RSV) vaccine in adults aged between 50 and 59.
GSK Stock Before Q2 Earnings: To Buy or Not to Buy?
We expect GSK's specialty products like Arexvy, Cabenuva, Juluca, Dovato, Trelegy Ellipta and Shingrix to drive second-quarter sales performance.
GSK (GSK) Earnings Expected to Grow: Should You Buy?
Glaxo (GSK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GSK Blenrep Combos for Multiple Myeloma Accepted for EU Review
GSK announces the acceptance of its regulatory filing, seeking the approval of Blenrep combinations for the treatment of relapsed or refractory multiple myeloma, for review in the EU.
Is GSK a Top-Value Stock Right Now?
GSK stock has a long track record of lagging behind the broader markets. Under CEO Emma Walmsley, the drugmaker has made significant strides toward improving its core-value proposition to shareholders.
Why GSK (GSK) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
The 3 Most Undervalued Pharma Stocks to Buy in July 2024
Undervalued pharma stocks can make good investments, whether during times of a booming economy or a faltering one. That is because people will still need medications and healthcare services regardless of the ongoing economic conditions.
Is GSK an Attractive Drug Stock to Add to Your Portfolio Now?
GSK plc GSK boasts a diversified base and presence in different geographical areas. The spin-off of the Consumer unit in 2022 has allowed it to focus on drug development.
Will GSK Stock Rebound To Its 2022 Highs Of $47?
GSK plc stock (NYSE: GSK) trades at $38 per share, about 20% below its peak level of over $47 seen in April 2022. In contrast, its peer Bristol Myers Squibb stock (NYSE: BMY) saw a 48% decline over this period.
GSK Buys Flu, COVID mRNA Jab Rights From Partner CureVac
GSK revamps its existing collaboration deal with partner CureVac, converting it from a collaboration deal into a licensing agreement related to mRNA vaccine candidates for COVID-19 and influenza.
